Mammography information system developer PenRad Technologies of Plymouth, MN, has signed an exclusive distribution agreement with GE Medical Systems of Waukesha, WI, to sell its PenRad Mammography Information System (MIS). The software is Windows
Mammography information system developer PenRad Technologies of Plymouth, MN, has signed an exclusive distribution agreement with GE Medical Systems of Waukesha, WI, to sell its PenRad Mammography Information System (MIS). The software is Windows NT-based and provides medical auditing, tracking, and scheduling. The alliance gives PenRad access to GEs extensive distribution networks, according to Gary Miars, executive vice president, and increases PenRads existing stable of OEM firms, which also includes Summit Medical Technologies of Arlington Heights, IL (SCAN 5/27/98).
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.